Medtronic (MDT) Q2 FY2024 earnings: revenue $8.0 billion, up 5.3% on the year
Medtronic plc (MDT) reported revenue of $8.0 billion for Q2 FY2024, the quarter ended 27 October 2023, up 5.3% on the same quarter a year earlier. Net income was $909 million, up 112.9% on the year, and diluted earnings per share $0.68. The figures are the company's own, from the 10-Q it filed with the SEC on 30 November 2023.
Revenue
$8.0 billion
+5.3% on the year · +3.7% on the quarter
Q3 FY2022Q2 FY2024
Operating margin
16.8%
18.5% a year earlier
Q3 FY2022Q2 FY2024
Net income
$909 million
+112.9% on the year · +14.9% on the quarter
Q3 FY2022Q2 FY2024
Diluted EPS
$0.68
+112.5% on the year · +15.3% on the quarter
Q3 FY2022Q2 FY2024
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
$ million
Q2 FY2024
Q1 FY2024
Q2 FY2023
On the quarter
On the year
Last 8 quarters
Revenue
7,984
7,702
7,585
+3.7%
+5.3%
Cost of revenue
2,761
2,628
2,535
+5.1%
+8.9%
Gross profit
5,223
5,074
5,050
+2.9%
+3.4%
Gross margin
65.4%
65.9%
66.6%
Research and development
698
668
676
+4.5%
+3.3%
Selling, general and administrative
2,686
2,613
2,617
+2.8%
+2.6%
Operating income
1,340
1,268
1,404
+5.7%
-4.6%
Operating margin
16.8%
16.5%
18.5%
Interest expense
180
148
118
+21.6%
+52.5%
Pre-tax income
1,313
1,196
1,395
+9.8%
-5.9%
Income tax
402
400
959
+0.5%
-58.1%
Effective tax rate
30.6%
33.4%
68.7%
Net income
909
791
427
+14.9%
+112.9%
Net margin
11.4%
10.3%
5.6%
Diluted EPS
$0.68
$0.59
$0.32
+15.3%
+112.5%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q2 FY2024
Q1 FY2024
Q2 FY2023
On the quarter
On the year
Last 8 quarters
Operating cash flow
661
875
922
-24.5%
-28.3%
Capital expenditure
461
354
323
+30.2%
+42.7%
Free cash flow
200
521
599
-61.6%
-66.6%
Free cash flow margin
2.5%
6.8%
7.9%
Cash from investing
-424
-539
-1,146
Cash from financing
-90.0
-501
3,014
Depreciation and amortisation
672
672
671
0.0%
+0.1%
Share-based compensation
146
73.0
137
+100.0%
+6.6%
Buybacks
226
152
141
+48.7%
+60.3%
Dividends paid
918
918
904
0.0%
+1.5%
Dividend per share
$0.69
$0.69
$0.68
0.0%
+1.5%
Diluted shares, weighted
1,332m
1,334m
1,332m
-0.1%
-0.0%
Shares outstanding at period end
1,330m
1,330m
1,330m
-0.0%
+0.0%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q2 FY2024
Q1 FY2024
Q2 FY2023
On the quarter
On the year
Last 8 quarters
Shareholders' equity
51,460
51,178
51,880
+0.6%
-0.8%
Non-controlling interest
187
188
177
-0.5%
+5.6%
Debt
25,080
24,982
26,617
+0.4%
-5.8%
Finance lease liabilities
56.0
57.0
55.0
-1.8%
+1.8%
Other liabilities
13,304
14,371
14,512
-7.4%
-8.3%
Total liabilities and equity
90,087
90,776
93,241
-0.8%
-3.4%
Fixed assets
5,735
5,665
5,298
+1.2%
+8.2%
Goodwill
40,821
41,436
40,417
-1.5%
+1.0%
Intangible assets
14,060
14,434
15,655
-2.6%
-10.2%
Investments
6,423
6,537
6,602
-1.7%
-2.7%
Cash and equivalents
1,311
1,339
4,828
-2.1%
-72.8%
Receivables
5,934
5,806
5,626
+2.2%
+5.5%
Inventory
5,754
5,668
5,055
+1.5%
+13.8%
Other assets
10,049
9,891
9,760
+1.6%
+3.0%
Total assets
90,087
90,776
93,241
-0.8%
-3.4%
Questions
What was Medtronic's revenue in Q2 FY2024?
Medtronic (MDT) reported revenue of $8.0 billion for Q2 FY2024, the quarter ended 27 October 2023, up 5.3% on the same quarter a year earlier.
How much did Medtronic earn in Q2 FY2024?
Net income for Q2 FY2024 was $909 million, up 112.9% on the year, and diluted earnings per share $0.68.
When did Medtronic report Q2 FY2024 results?
Medtronic filed its 10-Q for the quarter ended 27 October 2023 with the SEC on 30 November 2023.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 27 October 2023, filed 30 November 2023: the filing.